HPV typing
Identifying the patient's specific virus types before starting.
Cellular medicine · immunity
HPV — targeted cellular immunotherapy
If high-risk HPV doesn't clear on its own, there is a targeted immune-cell approach: your cells are activated against the identified virus types and returned to the body. It all starts with diagnostics and typing. The method does not replace screening, vaccination and standard treatment — a physician determines whether it's appropriate.
- Outpatient
- Based on HPV typing
- Your own cells
- Does not replace screening or vaccination
About the method
What is HPV — cellular immunotherapy
HPV (human papillomavirus) has more than 200 types. Low-risk types (6, 11) are linked to genital warts; persistent infection with high-risk types (16, 18, 31, 33, 45, 52, 58 and others) is a risk factor for precancerous changes of the cervix. The link between HPV and cervical cancer was established in the work of Harald zur Hausen (Nobel Prize 2008).
The method uses the patient's own immune cells: they are “trained” by loading them with antigens of the HPV types identified in you (from typing results), then returned to support a targeted immune response against infected cells and to regulate the immune environment. In China this belongs to third-category medical technologies (since 2009 cell therapy has been included in the relevant register of the National Health Commission).
The approach is always accompanied by diagnostics (a “three-step” model: cytology and HPV typing → colposcopy → biopsy if needed) and does not replace regular screening and vaccination.
How it works
The principle
Targeted cell activation
The patient's own immune cells are activated against the HPV types identified.
Individualised
The programme is built on diagnostic results; the physician decides.
Scientific basis
Origin and scientific basis
Facts about the method's origin, standards and quality control — what trust is built on. This is not a promise of a result: a physician decides whether it's right for you.
- Dendritic cells (DC)
The method is based on dendritic cells (DC) — the “mentors” that show the immune system which target to attack.
- Antigen loading
The approach of loading antigens onto DCs and activating an immune response is studied in immunotherapy; protocols are individual.
- Regulatory status in China
The field of cellular immune technologies was granted third-category status in China (2009).
The team
Specialist physicians for this area
This area in the cluster is led by specialist physicians with years of experience and academic credentials. They prescribe and deliver the treatment — MedBridge coordinates your route.
Luo ZhihuaInternal medicine · cellular technologiesA graduate of the University of Science and Technology of China (USTC). Internal medicine, 10+ years in practice; experience with stem cells, NK and CIK. Named “Best Doctor” of the Boao Lecheng zone (2019).
Who it's for
This may be relevant to you
Most people who consider this method recognise themselves in situations like these. It's not a prompt for self-treatment — whether it fits your case is decided by a physician after consultation and diagnostics.
- Persistent high-risk HPV
The virus isn't clearing on its own, and you want a concrete plan and oversight.
- You value privacy
You want to address a sensitive matter confidentially and at a high level.
- You act on data
You prefer virus typing and a precise strategy matched to the result.
- Already under observation
You're considering an additional method within standard care — by the physician's decision.
- You want it all organised
You need diagnostics, interpreting and support in one place, without chaos.
Why patients consider it
Why patients consider this method
These are reasons for interest in the method, not a promise of outcome: the physician sets the final decision and realistic expectations.
- Targeted and personal
Cells are activated against the HPV types identified in you — the approach is built on typing results.
- Your own biology
Your own immune cells are used; in China the method belongs to third-category medical technologies.
- Serious diagnostics
A three-step model: cytology and typing → colposcopy → biopsy if needed. The method does not replace screening and vaccination.
- Access, privacy, support
GMP / ISO standards in certified clinics of the zone, a personal coordinator and full confidentiality.
Indications
When it may be considered
May be considered by a physician for persistent HPV infection. This does not replace screening and vaccination; a specialist determines suitability.
- Persistent high-risk HPV infection
- HPV-associated conditions — as assessed by a physician
- Within observation and standard care
- Only after diagnostics and typing
Safety
Standards and quality control
The approach is built around patient safety and verifiable quality.
- The patient's own immune cells
- GMP / ISO standards in certified clinics of the cluster
- Mandatory diagnostics and typing before starting
- Under the supervision of relevant specialists
Process
How it goes
- 1Diagnostics and typing
Cytology, HPV typing, colposcopy by indication.
- 2Blood draw
The patient's venous blood (about 150–160 ml) to isolate and “train” the cells.
- 3Cell preparation
Cells are loaded with antigens of the identified HPV types and cultured for about 3 weeks.
- 4Administration
Targeted local administrations; a course usually involves several procedures at short intervals — by the physician's protocol.
- 5Follow-up
Review and re-examination in 3–6 months.
The physician determines the plan and realistic expectations. The method does not guarantee a result and does not replace screening, vaccination and standard treatment.
Outcomes
What to expect, and how progress is assessed
- Horizon of months, not days
The immune response forms gradually; review and re-examination at 3–6 months.
- Assessed by data
Dynamics are tracked by repeat HPV typing, cytology and, by indication, colposcopy.
- What it targets
Support for your own immune response against the HPV types identified — not a replacement for screening, vaccination and standard treatment.
- Honest expectations
The method does not guarantee clearance of the virus and is not a treatment for oncological disease; the physician determines strategy.
Safety
Risks, tolerability and contraindications
Openness about safety is part of a responsible approach.
- Your own cells
Your own immune cells are used, not donor material — immunological risks are minimal.
- Diagnostics mandatory before start
HPV typing, cytology and, if needed, colposcopy — the method does not start without them.
- Tolerability
Moderate local reactions are possible; serious reactions are rare. Individual tolerability is assessed by the physician.
- When it isn't performed
Contraindications usually considered include pregnancy, active concurrent infections and others. The method does not replace screening and vaccination; the physician decides.
Cost
Indicative cost
Approx. ¥148,000 (≈ $20,600)
The exact cost is determined only after diagnostics — the programme is tailored individually, by indication. Payment is made directly to the cluster's clinic, by official invoice. All prices →
Diagnostics — the required first step
Every programme begins with a consultation and an accurate diagnosis (check-up). Treatment does not start without assessing indications and contraindications.
Questions
FAQ — HPV — cellular immunotherapy
Yes. Every programme begins with a consultation and diagnostics (check-up). No therapy starts without an accurate diagnosis and assessment of contraindications — that is the basis of safety.
No. The method does not replace HPV vaccination and regular cervical screening — they remain the basis of prevention.
No. It is not a treatment for oncological disease and not a guarantee of its prevention. The physician determines strategy after diagnostics.
From the patient's own blood; the cells are activated against the HPV types identified at typing.
The active part is a few days (diagnostics, blood draw, administrations by protocol); follow-up at 3–6 months can be done locally. Exact timing is agreed in advance.
No. The method does not replace standard care for identified cervical changes; the decision to treat is made by the physician.
The volume of diagnostics and the programme. See the Pricing page for a guide; the exact estimate is formed after diagnostics and paid directly to the clinic.
Discuss the programme with a coordinator
Tell us your situation and medical goal — we'll advise which documents help prepare a preliminary review and what the next steps could be.